Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

1. PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis.
Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly
impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently,
tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for
the vast majority of global sales, with the US adolescent market being the key target segment.
GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better
protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share
during 2012-2022.
Scope
Overview of meningococcal disease, including epidemiology, etiology, general symptoms from infection,
and national vaccination recommendations and guidelines. Annualized meningococcal vaccine market
revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to
2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs,
clinical trial mapping and implications for the meningococcal vaccine market. Pipeline analysis:
comprehensive data split across different phases and emerging trends, specifically serotype B vaccines and
early stage infant and pentavalent vaccines. Analysis of the current and future market competition in the global
meningococcal vaccine market. Insightful review of the key industry and governmental drivers, restraints and
challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and
high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,
patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10
year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our
models support data presented in the reports and the complete methodology is outlined in the report and the
model.
*Model only available with site and global license purchases.
Key Findings
Country-specific epidemiology and serotype distributions heavily influence immunization recommendations
and vaccine usage. Serotype B vaccines are expected to drive growth of the market space during the forecast
period. Major players will leverage their R&D, manufacturing, and distribution networks to maintain their
stakes in the market. Government endorsements of new and existing vaccines are anticipated to dramatically
influence market growth. Key Questions Answered in this Report
How large an impact will serotype B vaccines have on the meningococcal market? What do key opinion
leaders think of these vaccines? What are the key vaccines for each age segment and country? Which
meningococcal vaccines will face adoption challenges in the market? What is the projected uptake of new
vaccines, such as Novartis’ Bexsero, over the forecast period? The developmental pipeline consists of
vaccines that address serotype B protection and immunogenicity in infants. Which of these vaccines will attain
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

2. high sales revenues during 2012-2022 and in which markets? What governmental and industry developments
are likely to affect the vaccination rates in the markets researched? Which is the largest growth market
globally?
Key Benefits Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most robust pipeline. Develop business
strategies by understanding the trends shaping and driving the meningococcal vaccine market. Drive revenues
by understanding the key trends, innovative products and technologies, market segments, and companies
likely to impact the global meningococcal vaccine market in future. Formulate effective sales and marketing
strategies by understanding the competitive landscape and by analyzing the performance of various
competitors. Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage. Track drug sales in the global meningococcal vaccine
market from 2012-2022. Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and strategic partnerships.
table Of Contents
1table Of Contents2
1.1list Of Tables8
1.2list Of Figures11
2meningococcal Vaccines: Executive Summary12
2.1meningococcal Vaccine Sales Expected To Grow During The Forecast Period13
2.2vaccine Manufacturers Concentrate On Unexploited Segments Of The Market, As Exemplified By
Serogroup B Vaccine Development14
2.3healthcare Providers Clamor For Cost-effective Vaccines That Provide Broader Serogroup Coverage15
2.4serogroup B Vaccines Are Primed For Strong Market Debuts By Offering Unprecedented Serogroup
Coverage16
2.5serogroup B Vaccines Will Stimulate Robust Growth In The Meningococcal Vaccines Market16
2.6what Do The Physicians Think?17
3introduction19
3.1catalyst19
3.2related Reports19
3.3upcoming Related Reports19
4disease Overview21
4.1etiology And Pathophysiology21
4.1.1etiology21
4.1.2pathophysiology23
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

3. 4.2symptoms23
4.3prognosis24
5epidemiology25
5.1disease Background25
5.2risk Factors And Co-morbidities25
5.2.1infants And Young Children Are At Greatest Risk For Developing Meningococcal Disease26
5.2.2direct Contact And Overcrowding Are The Primary Risk Factors For Infection26
5.2.3exposure Is Highest For Those Traveling To The African “meningitis Belt”27
5.3global Trends28
5.3.1us28
5.3.25eu28
5.3.3australia29
5.3.4brazil30
5.4forecast Methodology30
5.4.1sources Used31
5.4.2forecast Assumptions And Methods34
5.4.3sources Not Used37
5.5epidemiology Forecast Of Meningococcal Disease (2012-2022)37
5.5.1incident Cases Of Meningococcal Disease37
5.5.2age-specific Incident Cases Of Meningococcal Disease39
5.5.3incident Cases Of Meningococcal Disease By Serogroup41
5.6discussion43
5.6.1conclusions On Epidemiological Trends43
5.6.2limitations Of The Analysis44
5.6.3strengths Of The Analysis44
6disease Management46
6.1meningococcal Immunization Policy46
6.2us48
6.2.1meningococcal Immunization Recommendations And Policies48
6.2.2clinical Practice49
6.3france51
6.3.1meningococcal Immunization Recommendations And Policies51
6.3.2clinical Practice52
6.4germany53
6.4.1meningococcal Immunization Recommendations And Policies53
6.4.2clinical Practice54
6.5italy54
6.5.1meningococcal Immunization Recommendations And Policies54
6.5.2clinical Practice55
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

4. 6.6spain55
6.6.1meningococcal Immunization Recommendations And Policies55
6.6.2clinical Practice56
6.7uk57
6.7.1meningococcal Immunization Recommendations And Policies57
6.7.2clinical Practice58
6.8japan59
6.8.1meningococcal Immunization Recommendations And Policies59
6.8.2clinical Practice59
6.9australia60
6.9.1meningococcal Immunization Recommendations And Policies60
6.9.2clinical Practice61
6.10brazil62
6.10.1meningococcal Immunization Recommendations And Policies62
6.10.2clinical Practice62
7competitive Assessment64
7.1overview64
7.2strategic Competitor Assessment64
7.3product Profiles – Major Brands65
7.3.1menactra65
7.3.2menveo69
7.3.3nimenrix72
7.3.4menhibrix75
7.3.5menitorix78
7.3.6meningitec81
7.3.7menjugate84
7.3.8neisvac-c86
7.3.9menomune89
7.3.10bexsero93
8opportunity And Unmet Need97
8.1overview97
8.2unmet Needs97
8.2.1unmet Need: Protection Against Serogroup B Disease97
8.2.2unmet Need: A Pentavalent (menabcwy) Vaccine98
8.2.3unmet Need: More Cost-effective Vaccines99
8.2.4unmet Need: Improved Duration Of Immunity In Children And Adolescents99
8.2.5unmet Need: Immunogenic Infant Vaccines100
8.2.6unmet Need: Improved Vaccination Coverage Rates101
8.2.7unmet Need: Increased Patient Awareness And Education102
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

5. 8.3unmet Needs Gap Analysis102
8.4opportunities103
8.4.1opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations103
8.4.2opportunity: Improving Immune Response Duration With Adjuvants103
8.4.3opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets104
9pipeline Assessment105
9.1overview105
9.2clinical Trial Mapping105
9.2.1clinical Trials By Country105
9.3clinical Trials By Phase And Trial Status107
9.4promising Vaccines In Clinical Development108
9.4.1mnb Rlp2086110
9.5promising Vaccines In Early Clinical Development114
9.5.1meninge Acyw Conj.114
9.5.2menabcwy117
9.5.3menc Conjugate119
9.5.4heptavalent Dtp-hib-hepb-ipv-menc121
10current And Future Players123
10.1overview123
10.2trends In Corporate Strategy125
10.3company Profiles126
10.3.1sanofi126
10.3.2novartis129
10.3.3glaxosmithkline131
10.3.4baxter133
10.3.5nuron Biotech134
10.3.6pfizer136
11market Outlook138
11.1global Markets138
11.1.1forecast138
11.1.2drivers And Barriers – Global Issues140
11.2united States143
11.2.1forecast143
11.2.2key Events145
11.2.3drivers And Barriers146
11.3france149
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

6. 11.3.1forecast149
11.3.2key Events151
11.3.3drivers And Barriers152
11.4germany153
11.4.1forecast153
11.4.2key Events155
11.4.3drivers And Barriers156
11.5italy157
11.5.1forecast157
11.5.2key Events159
11.5.3drivers And Barriers160
11.6spain161
11.6.1forecast161
11.6.2key Events164
11.6.3drivers And Barriers164
11.7united Kingdom165
11.7.1forecast165
11.7.2key Events168
11.7.3drivers And Barriers169
11.8japan170
11.8.1drivers And Barriers170
11.9australia171
11.9.1forecast171
11.9.2key Events174
11.9.3drivers And Barriers175
11.10brazil176
11.10.1forecast176
11.10.2key Events178
11.10.3drivers And Barriers179
12appendix181
12.1bibliography181
12.2abbreviations194
12.3methodology196
12.4forecasting Methodology196
12.4.1vaccine Coverage196
12.4.2vaccine Approval Vs. Routine Schedule Inclusion197
12.4.3vaccines Included197
12.4.4key Launch Dates197
12.4.5general Pricing Assumptions198
12.4.6individual Vaccine Assumptions199
12.4.7pricing Of Pipeline Agents204
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

7. 12.5physicians And Specialists Included In This Study205
12.6about The Authors208
12.6.1authors208
12.6.2reviewers208
12.6.3epidemiologists208
12.6.4global Head Of Healthcare209
12.7about Globaldata210
12.8contact Us210
12.9disclaimer210
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022